Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam besylate + etomidate vs cyclopropofol for painless gastrointestinal endoscopy
ChiCTR2400092309Phase 4Not yet recruiting
- Sponsor
- Deyang People's Hospital
- Start
- Nov 2024
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in procedural pain, hypopnea and hypotension comparing Cyclopropofol group with Remimazolam besylate + etomidate group (2 arms). Primary endpoint: Incidence of respiratory depression. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
remimazolametomidateciprofol
03
Conditions
procedural painhypopneahypotension
Beyond the preview
Go deeper on ChiCTR2400092309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092309.